secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001808805-23-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotech Q1 net loss $15M, cash $302M; platform launch mid-2024
-----------------------------------------------------------------------

- Net loss $15.0M vs $15.8M year ago; operating expenses $18.1M, up 13% YoY on higher headcount.
- Cash, equivalents and investments $302.0M as of March 31, 2023; runway expected into 2025.
- Platform (instruments, reagents, software) launch planned for mid-2024.
- Granted 4 new US patents in Q1, raising total to 12 granted patents.
- Announced three winners of First Access Challenge for Early Access Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/0001808805-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000045/naut-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001808805-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer